人民财讯11月26日电，11月26日，甘李药业（603087）宣布公司自主研发的胰高血糖素样肽-1受体激动 剂(GLP-1RA)博凡格鲁肽(研发代号：GZR18)注射液正式启动一项针对肥胖或超重适应症的III期临床试 验(GRADUAL-3)，这是博凡格鲁肽在肥胖/超重领域开展的第三项大规模III期临床研究。该研究将采取 每四周一次皮下注射给药的月制剂方案，旨在探索博凡格鲁肽注射液在控制和维持体重方面的临床潜 力。 ...

中证报中证网讯（王珞）11月25日，甘李药业（603087）宣布，与拉丁美洲知名制药企业Productos Científicos S.A. de C.V.（以下简称：PC）达成独家许可与商业化供应协议，授权其在拉丁美洲地区（包 括墨西哥、巴西等重点国家）开发及商业化甘李自主研发的胰高血糖素样肽-1受体激动剂（GLP-1RA） 双周制剂博凡格鲁肽（GZR18）。此次合作标志着甘李药业首次实现了自主创新药的国际化输出，也开 启了甘李创新药在拉美的全新商业化布局。 拉美GLP-1市场潜力巨大 双周制剂优势显著 此次合作将甘李药业的创新研发能力与合作伙伴的本地优势相结合，共同开拓快速增长的市场。公开资 料显示，拉美地区糖尿病与肥胖患病率长期处于高位，对相关治疗方案的需求持续攀升。2024年，拉丁 美洲GLP-1受体激动剂市场规模达到13.23亿美元。根据行业预测，到2030年该市场规模有望突破35亿美 元，2025-2030年复合年增长率高达16.8%。 在拉美地区对用药便捷性和治疗依从性要求不断提升的背景下，双周给药的GLP-1RA制剂因给药频次 更低、治疗体验更佳而展现出明显优势。合作方PC公司计划将在墨西哥、 ...

11月25日，甘李药业（603087.SH）宣布，与拉丁美洲知名制药企业Productos Científicos S.A. de C.V. （以下简称：PC）达成独家许可与商业化供应协议，授权其在拉丁美洲地区(包括墨西哥、巴西等重点 国家)开发及商业化甘李自主研发的胰高血糖素样肽-1受体激动剂（GLP-1RA）双周制剂博凡格鲁肽 （GZR18）。此次合作标志着甘李药业首次实现了自主创新药的国际化输出，也开启了甘李创新药在拉 美的全新商业化布局。 国际化战略双线告捷 资本市场成长路径清晰 本次授权是甘李药业在拉美市场取得的第二项重大突破。就在今年9月，公司已通过与巴西本土药企的 合作，签下了一份总金额不低于30亿元人民币的长期供应协议。 这两项合作分别针对"成熟产品"与"创新管线"，清晰地勾勒出公司双轮驱动的国际化战略：一方面通过 技术转移和供应链合作，稳固收入基本盘；另一方面通过创新药授权，打开长期估值空间，向资本市场 展示了从"中国制造"到"中国智造"的升级路径。 业绩与研发共振 创新价值进入兑现期 资本市场分析指出，甘李药业正迎来"国内复苏"与"国际加速"的双重动力。据华安证券研报，2025年上 半年公 ...

Core Insights - 甘李药业 has been recognized as a manufacturing single champion enterprise, marking its status as a leading company in the biopharmaceutical sector with its core product, "Insulin Glargine Injection" [1][2] - The recognition reflects 甘李药业's advanced production technology and significant market share in the insulin analogs field, breaking the long-standing foreign monopoly in the domestic insulin market [1][2] Group 1: Company Achievements - 甘李药业 has established a self-controlled production system and a complete product line, including long-acting, rapid-acting, and premixed insulin [2] - The company has successfully passed the European Medicines Agency (EMA) GMP inspection, laying a solid foundation for entering the global regulated market [2] - In the first three quarters of 2025, domestic formulation revenue reached 2.624 billion yuan, a year-on-year increase of 45.6%, indicating a robust recovery in the domestic market [2] Group 2: Innovation and Future Prospects - Under the leadership of CEO Dr. Chen Wei, 甘李药业 is accelerating the development and global registration of innovative drugs, transitioning from "China's first imitation" to "global first creation" [3] - The company is expected to play a more significant role in the global value chain of the pharmaceutical industry, driven by steady growth in the domestic procurement market and accelerated expansion in the international high-end market [3]

Core Viewpoint - 甘李药业's stock has experienced fluctuations, with a year-to-date increase of 49.24% and a recent decline of 9.25% over the past 20 days, indicating volatility in its market performance [1][2]. Financial Performance - For the period from January to September 2025, 甘李药业 reported a revenue of 3.047 billion yuan, representing a year-on-year growth of 35.73%. The net profit attributable to shareholders was 818 million yuan, reflecting a significant increase of 61.32% compared to the previous year [2]. - The company has distributed a total of 1.612 billion yuan in dividends since its A-share listing, with 1.018 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for 甘李药业 increased to 94,700, marking a rise of 22.53%. The average number of circulating shares per shareholder decreased by 17.81% to 5,889 shares [2]. - The top ten circulating shareholders include significant institutional investors, with Hong Kong Central Clearing Limited holding 8.0042 million shares, an increase of 494,300 shares from the previous period [3].

Core Points - The first extraordinary general meeting of shareholders for 2025 was held on November 17, 2025, at the company's conference room in Tongzhou District, Beijing [2] - All resolutions proposed during the meeting were approved without any dissenting votes [2][4] - The meeting was legally convened and conducted in accordance with the Company Law of the People's Republic of China and the company's articles of association [2][7] Meeting Attendance - The meeting was chaired by the company's chairman, Mr. Chen Wei, with the attendance of all current directors and supervisors [2][3] - The company secretary and other senior executives were also present at the meeting [3] Resolutions Reviewed - The resolution to cancel the supervisory board and amend the articles of association was passed with more than two-thirds of the voting rights [4][6] - Several governance documents were revised and approved, including rules for shareholder meetings, board meetings, external guarantee systems, investment management methods, and related party transaction management [5][6] - A new remuneration management method for directors and senior management was established and approved [5][6] Legal Verification - The meeting was witnessed by lawyers from Zhonglun Law Firm, who confirmed that all procedures and resolutions complied with legal and regulatory requirements [7] Board Changes - Non-independent director Mr. Xu Fuming submitted his resignation due to adjustments in the company's governance structure, effective immediately upon receipt by the board [9][11] - Mr. Xu will continue to hold other positions within the company [9][11] - A new employee representative director was elected during the employee representative meeting held on November 17, 2025, following the approval of the supervisory board cancellation [12]

Group 1 - The company announced the election of Xu Fuming as the employee representative director of the fifth board of directors during the employee representative assembly held on November 17, 2025 [2]

Core Viewpoint - Gann Li Pharmaceutical (甘李药业) announced a governance structure adjustment, leading to the resignation of Xu Fuming from his position as a non-independent director of the fifth board of directors, while he will continue to hold other roles within the company [1] Group 1 - Xu Fuming applied to resign from his position as a non-independent director of the fifth board of directors [1] - Following his resignation, a workers' representative meeting was held to elect Xu Fuming as a workers' representative director of the fifth board of directors [1] - Xu Fuming's term as a workers' representative director will last until the end of the fifth board's term [1]

第二条 本办法适用于公司董事、高级管理人员。 第三条 公司董事和高级管理人员薪酬将与公司经营业绩相结合，保障公司 稳定发展，但同时符合市场价值规律，公司薪酬制度遵循以下原则： （一）按岗位确定薪酬原则：公司内部各岗位薪酬体现各岗位对公司的价值； 甘李药业股份有限公司 董事、高级管理人员薪酬管理办法 第一章 总则 第一条 为进一步完善甘李药业股份有限公司（以下简称"公司"）董事、 高级管理人员的薪酬管理，建立和完善经营者的激励约束机制，保持核心管理团 队的稳定性，有效地调动董事、高级管理人员的工作积极性，提高公司经营管理 水平，促进公司健康、持续、稳定发展，根据《中华人民共和国公司法》《上市 公司治理准则》等有关法律、法规的规定及《甘李药业股份有限公司章程》（以 下简称《公司章程》），结合公司的实际情况，特制定本办法。 （二）按绩效评价标准、程序及主要评价体系的原则； （三）个人薪酬与公司长远利益相结合的原则； （四）激励与约束并重、奖罚对等的原则。 第二章 薪酬决策机构 第四条 公司董事会负责审议公司高级管理人员的薪酬；公司股东会负责审 议董事的薪酬。 第五条 公司董事会薪酬与考核委员会负责制定公司董事、高级 ...

甘李药业股份有限公司 对外投资管理办法 第一章 总则 第一条 为规范甘李药业股份有限公司（以下简称"公司"）及公司的全资、 控股子公司的投资行为，降低投资风险，提高投资效益，依照《公司法》等国家 有关法律、法规及公司章程，制定本制度。 第二条 本制度所指投资仅指权益性投资。权益性投资包括各项股权投资、 债权投资、产权交易、公司重组以及合资合作等。 （四）与公司财务管理部门共同参与投资项目终（中）止清算与交接工作； （五）本制度规定的其他职能。 重大资本性支出如购置消费类资产（如车辆）、超过年度经营计划的技术改 造、基本建设、重大固定资产购置等不在本制度规范之内。 第三条 投资管理遵循的基本原则为：符合公司发展战略，合理配置企业资 源，促进要素优化组合，创造良好经济效益。 第二章 投资决策和管理机构 第四条 公司股东会、董事会依据公司章程确定的权限范围和程序对公司的 对外投资进行决策。 公司所有投资活动实行归口管理，公司投资管理部门由董事会确定。 第五条 公司投资管理部门的基本职能如下： （一）根据公司经营目标和发展规划编制并指导实施投资计划； （二）对投资项目的预选、策划、论证及实施进行管理与监督； （三）负 ...